News | July 11, 2023
Briefs: Link Pharma Chem and Zydus
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Construction will begin this year with the new capacity anticipated by 2025
Subscribe To Our Newsletter & Stay Updated
